Education
About Us
Working with TipRanks
Follow Us
Clearside Biomedical (CLSD)
NASDAQ:CLSD
CLSD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.77 - $1.73
Previous CloseN/A
Volume106.43K
Average Volume (3M)211.46K
Market Cap
$77.36M
Enterprise Value$121.31M
Total Cash (Recent Filing)$8.04M
Total Debt (Recent Filing)$9.97M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Mar 27, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding75,843,506
10 Day Avg. Volume137,316
30 Day Avg. Volume211,458
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.90
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.41
Enterprise Value/Ebitda-5.46
Forecast
1Y Price Target
$5.25Price Target Upside409.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase 2b ODYSSEY trial hit expectations with CLS-AX showing competitive durability, which is expected to send CLSD shares higher.
Regulatory ApprovalFDA has approved the proposed Phase 3 program for CLS-AX in wAMD.
Bears Say
Financial NeedsCLSD ended 3Q24 with $24M in cash which provides runway into 3Q25, so management will need a capital infusion to kick off its Phase 3 trials in 2H25 as planned.
Funding RequirementsThe company needs to secure funding or a partnership to conduct the Phase 3 program for CLS-AX.
---
Ownership Overview
1.83% Insiders
4.93% Mutual Funds
4.12% Other Institutional Investors
85.27% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CLSD FAQ
What was Clearside Biomedical’s price range in the past 12 months?
Clearside Biomedical lowest stock price was $0.77 and its highest was $1.73 in the past 12 months.
What is Clearside Biomedical’s market cap?
Clearside Biomedical’s market cap is $77.36M.
When is Clearside Biomedical’s upcoming earnings report date?
Clearside Biomedical’s upcoming earnings report date is Mar 27, 2025 which is yesterday.
How were Clearside Biomedical’s earnings last quarter?
Clearside Biomedical released its earnings results on Mar 27, 2025. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.098 by -$0.002.
Is Clearside Biomedical overvalued?
According to Wall Street analysts Clearside Biomedical’s price is currently Undervalued.
Does Clearside Biomedical pay dividends?
Clearside Biomedical does not currently pay dividends.
What is Clearside Biomedical’s EPS estimate?
Clearside Biomedical’s EPS estimate is -0.1.
How many shares outstanding does Clearside Biomedical have?
Clearside Biomedical has 75,843,506 shares outstanding.
What happened to Clearside Biomedical’s price movement after its last earnings report?
Clearside Biomedical reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.098. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Clearside Biomedical?
Currently, no hedge funds are holding shares in CLSD
---
Clearside Biomedical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.25 (409.71% Upside)
$5.25 (409.71% Upside)
Insider Transactions
Bought Shares
Worth $13.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.64%
12-Months-Change
Fundamentals
Return on Equity
91.63%
Trailing 12-Months
Asset Growth
-15.28%
Trailing 12-Months
Company Description
Clearside Biomedical
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
---
CLSD Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and regulatory approvals, particularly in the Asia-Pacific region. However, the company faces challenges in securing funding for its Phase 3 program, which is crucial for its future success. The sentiment is positive due to the strong trial results and strategic partnerships, despite the funding and enrollment challenges.Read More>---
CLSD Stock 12 Month Forecast
Average Price Target
$5.25
▲(409.71% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Madrigal Pharmaceuticals
―
Aldeyra Therapeutics
―
Ocular Therapeutix
―
Kala Pharmaceuticals
―
Best Analysts Covering CLSD
1 Year
1 Year Success Rate
8/15 ratings generated profit
1 Year Average Return
+3.39%
reiterated a buy rating 23 days ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +3.39% per trade.
---